Skip to content

Continuous Sciatic Nerve Block vs Epidural Analgesia in Lower Limb Amputation for Postoperative Pain

Continuous Sciatic Nerve Block vs Epidural Analgesia in Lower Limb Amputation for Prevention of Acute Postoperative Pain and Phantom Limb Pain: A Triple-blind Randomized Controlled Non-inferiority Clinical Trial.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05608733
Acronym
Ampupain
Enrollment
112
Registered
2022-11-08
Start date
2022-12-31
Completion date
2025-07-31
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phantom Limb Pain, Pain, Chronic

Brief summary

Controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants

Detailed description

Controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants Outcomes: Primary: Numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain) was used for pain assessments daily for 15 days and subsequently monthly until completing 3 months. Co-primary: Assessment of symptomatology related to phantom limb pain daily for 15 days POP and subsequently monthly until completing 3 months.

Interventions

Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.

The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.

Sponsors

Universidad de Antioquia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age over 18 years 2. Being scheduled for above or below knee amputation or for bone remodeling of lower limb amputees 3. Acceptance of continuous regional analgesic technique as part of their multimodal analgesia

Exclusion criteria

1. Traumatic cause of amputation 2. Allergy to local anesthetics 3. Contraindication for epidural technique or continuous blocks 4. Stage 5 kidney disease 5. Concomitant use of aspirin and clopidogrel 6. Pregnancy status

Design outcomes

Primary

MeasureTime frameDescription
Phantom Limp Pain3 monthsFor this qualitative dichotomous outcome, you will ask about symptomatology referring to phantom limb pain for 15 days POP and subsequently monthly until completing 3 months, It will be qualified as positive if it presents any neuropathic symptom.
Posoperative Pain3 monthsPain score according to the daily NRS scale (Numeric Pain Rating Scale), Numeric Pain Rating Scale, for 15 days POP and subsequently monthly until completing 3 months. is scores from 0 to 10, 10 being the worst value.

Secondary

MeasureTime frameDescription
Opioid Consumption36 hoursthe total consumption in mg of morphine or its equivalent at 12, 24 and 36 h POP will be evaluated.
Incidence of nausea and vomiting POP36 hoursIncidence of nausea and vomiting POP in each group: the appearance of nausea or vomiting at 12, 24 and 36 h POP will be asked.
Days of hospital stayduring the time of hospitalization, on average 10 daysDays of hospital stay through study completion
Mortality1 yearMortality in the first Year
Incidence of adverse effects1 yearany appearance of hematoma, hypotension (defined as SBP less than 90 mmHg or a 30% decrease in baseline MAP) or bradycardia (HR less than 60 bpm) is defined.
Phantom Limp Pain first Year1 yearPresence of phantom limb pain on a monthly basis until completing 12 month, The patient will be asked about the appearance of any painful sensation described as stabbing, shooting, electric shock, dull, tight pain and/or cramp in the anatomical site where the amputated limb would be, evaluating the presence or absence of the same (s). This will be questioned every day for 15 POPs days and monthly follow-up will continue via telephone until completing 3 months.

Other

MeasureTime frameDescription
Posoperative Satisfaction36 hoursPostoperative satisfaction measured with the EVAN LR scale (evaluation of local anesthetic satisfaction). It consists of a self-reported scale that measures satisfaction in the postoperative period of patients undergoing regional anesthesia in different surgical models (51), with an evaluation of 19 items structured in a global index and five unweighted dimensions, each of which covers some aspects such as Attention (4 items), Information (5 items), Discomfort (4 items), Waiting (2 items) and Pain (4 items). has a score for questions between 20 and 100 points, the lower the score, the lower satisfaction by dimension

Countries

Colombia

Contacts

Primary ContactDaniela González, Md
daniela.gonzalezg@udea.edu.co3122690961
Backup ContactLaura Lopez Agudelo, Md
laura.lopez9@udea.edu.co3148874442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026